Басты бетке

3 бет - Ең жақсы қуық рагының дәрігерлері - ЖОҒ-93 дәрігерлер

Контент Bookimed редакциялық саясатына сәйкес келеді және оның сапасын тексерген

Фахад Мавлюд

Atakan Topcu

  • 5 Керемет 3 пікірлер
  • 12 жылдар тәжірибе
  • Түркия, Істанбұл, Medipol Acibadem District Hospital
  • Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

    He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

    Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Svetlana Zalmanova

  • 4.4 Жақсы 13 пікірлер
  • Израиль, Тель-Авів, Assuta Medical Center
  • Radiotherapist

Ақпарат

Gilad Amiel

  • 5 Керемет 2 пікірлер
  • Израиль, Хайфа, Rambam Medical Center
  • Head of Rambam Department of Urology, Oncosurgeon

Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Choi Han Yong

  • 4.5 Жақсы 22 пікірлер
  • Оңтүстік Корея, Сеул, Samsung Medical Center
  • Oncosurgeon, Head of Samsung Department of Urology

Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Eduard Becht

  • 4.5 Жақсы 52 пікірлер
  • Германия, Майндағы Франкфурт, Nordwest Clinic (Krankenhaus)
  • Prof. Dr. Eduard Becht is a Urologist in Germany with 41 years of experience and holds an honorary doctorate from Kapodiastrias University of Athens. He is a lecturer at Goethe University in Frankfurt am Main since 1994 and specializes in Urological Oncology, Minimally Invasive Treatment of Prostate Cancer, Kidney Tumor Operation, Urethral Surgery, Pediatric Urology and Kidney Stone Treatment. He has published over 100 scientific papers.

  • Толығырақ оқу
Ақпарат

Amnon Zisman

  • 4 Жақсы 1 пікірлер
  • Израиль, Герцлія, Herzliya Medical Center
  • Urologist, Surgeon

Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Seyda Gunduz

  • 4.4 Жақсы 17 пікірлер
  • 15 жылдар тәжірибе
  • Түркия, Істанбұл, Istinye University Liv Hospital Bahcesehir
Ақпарат

Inta Jaunalksne

  • 5 Керемет 2 пікірлер
  • 48 жылдар тәжірибе
  • Латвия, Юрмала, Pallas Clinic
  • Dr. Inta Jaunalksne is an experienced immunologist with more than 30 years in the field. She specializes in virotherapy. She graduated from Riga Medical Institute and completed an internship in Internal Medicine. Dr. Jaunalksne is recognized as an expert in immunology.

    She leads the Clinical Immunology Center at Pauls Stradins Clinical University Hospital. Dr. Jaunalksne has played a key role in advancing virotherapy and immunological research. Her work has improved treatment results and introduced new therapies. She is well respected in clinical immunology.

  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Nail Paksoy

  • 4.5 Жақсы 2 пікірлер
  • 14 жылдар тәжірибе
  • аккредитациялар:
  • Түркия, Істанбұл, Medipol Bahçelievler Hospital

  • PROFESSIONAL EXPERIENCE

    2011-2012
    Erzurum Koprukoyu State Hospital
    Department: General Medicine

    2012-2017
    Istanbul University Cerrahpaşa Medical Faculty
    Department: Internal Medicine

    06/2017-10/2017
    Istanbul Gaziosmanpasa Taksim Training and Research Hospital
    Department: Internal Medicine

    10/2017-11/2018
    Istanbul University Istanbul Medical Faculty
    Department: Allergy and Immunology Fellowship

    2018/2022
    Istanbul University Oncology Institute
    Department: Medical Oncology Fellowship

    2022-2023
    Tekirdag City Hospital
    Department: Medical Oncology Specialist

    2023-present
    Istanbul Medipol University Medipol Bahcelievler Private Hospital
    Department: Medical Oncology Assoc. Prof.

     

    EDUCATION

    2005-2011
    Medical Education
    Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

    2012-2017
    Internal Medicine
    Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

    2017-2018
    Allergy-Immunology Fellowship
    Istanbul University Istanbul Medical Faculty
    Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

    2018-2022
    Medical Oncology Fellowship
    Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

    2022
    ESMO Board Certification in Medical Oncology
    10th September 2022 in Paris, France.

    2023
    Medical Oncology Assoc. Prof.
    Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

     

    INTERNATIONAL CLINICAL TRIALS:

    1. Astefania - ROCHE

    • Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
    • Role: Subinvestigator

    2. PFİZER

    • Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
    • Role: Subinvestigator

    3. RECITE - AMGEN

    • Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
    • Role: Subinvestigator

    4. NAVIGATE - BAYER

    • Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
    • Role: Subinvestigator

    5. RUBY - Tesaro (PRA)

    • Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
    • Role: Subinvestigator

    6. ENGOT-ov43/GOG-3036 - MSD

    • Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
    • Role: Subinvestigator

    7. ASTRA ZENECA

    • Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
    • Role: Subinvestigator

    8. ROSY-O - ASTRA ZENECA

    • Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
    • Role: Subinvestigator
    •  

    INTERNATIONAL PUBLICATIONS

    I. Published journal articles indexed by SCI, SSCI, and AHCI

    Weekly Paclitaxel in Classic Kaposi Sarcoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
    • Journal: Medicine, 102(5)

    Carboplatin Desensitization in Ovarian Carcinoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
    • Journal: Medicine, 101(45), e31726

    High-Dose Chemotherapy for Ewing’s Sarcoma

    • Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
    • Journal: Medicine, 101(49), e32213

    Multidrug Refractory TFE3(+) Renal Cell Carcinoma

    • Authors: Paksoy, Nail, et al.
    • Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

    Crizotinib Efficacy in NSCLC with MET Alterations

    • Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
    • Journal: Medicine, 101(50), e32368

    Clinicopathological Features in ALK Mutant NSCLC

    • Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
    • Journal: Medicine, 101(34)

    PSMA-Based Tumor Burden in Prostate Cancer

    • Authors: HAS SIMSEK, Duygu, et al.
    • Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

    Atezolizumab in Metastatic Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: European Urology Focus, 2021, 7.5: 1061-1066

    Pulmonary Sarcomatoid Carcinoma

    • Authors: FERHATOGLU, Ferhat, et al.
    • Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

    Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

    Atezolizumab with Chemotherapy in Small Cell Lung Cancer

    • Authors: GÜRBÜZ, Mustafa, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

    FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

    • Authors: AY, Seval, et al.
    • Journal: Journal of Chemotherapy, 2022, 1-7

    Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

    • Authors: CIL, Ibrahim, et al.
    • Journal: Tumori Journal, 2022, 108.1: 19-25

    Real-Life Efficacy of Osimertinib in Advanced NSCLC

    • Authors: HIZAL, Mutlu, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

    ALK-Positive Cells Percentage and Alectinib Efficacy

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
    • Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

    Real-World Data on Alectinib in ALK-Positive NSCLC

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
    • Journal: Future Oncology, 18(23), 2573-2582

    Prognostic Factors in Metastatic RCC with T790M Mutation

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

    • Authors: DEMIR, Semra, et al.
    • Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

    Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

    • Authors: ÖZDEMIR, Seçil Kepil, et al.
    • Journal: Allergy, 2019, 74.6: 1187-1190

    Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

    • Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
    • Journal: The Oncologist, oyad257

    Subsequent Treatments in Hormone-Positive Breast Cancer Progression

    • Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
    • Journal: BMC cancer, 23(1), 192

    Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
    • Journal: Scientific Reports, 13(1), 8779

    Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
    • Journal: Journal of Cancer Research and Clinical Oncology, 1-9

    Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

    • Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
    • Journal: European Journal of Breast Health, 19(2), 128

    Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

    • Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
    • Journal: Future Oncology, 19(10), 727-736

    Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

    • Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
    • Journal: [Not specified]

    Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

    • Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
    • Journal: Medicine, 102(39), e35383

    Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

    • Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
    • Journal: Medicine, 102(41), e35245

    Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

    Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

    Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

    Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

    Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

    Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

    Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

    Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

    Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

    Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

    Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

    Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

    Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

     

    Thesis:

    Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

    International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

    Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

    • Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

    Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

    • Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

    Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

    • Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

    Efficacy of temozolomide in pretreated patients with metastatic sarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

    • Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

    • Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

    Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

    • Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

    Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

    • Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

    Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

    • Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

     

     

  • Толығырақ оқу
Қуықты алып тастау
$8,000 - $12,000
Іш қуысына жіті енгізілетін химиотерапия HIPEC
$18,000 - $25,000
Тік ішек қатерлі ісігінде сәулелік терапия
$4,000 - $6,000
Ақпарат

Serap Kaya

  • 4.4 Жақсы 32 пікірлер
  • 25 жылдар тәжірибе
  • Түркия, Істанбұл, Emsey Hospital
  • Dr. Serap Kaya is a medical oncologist with a specialization in Medical Oncology from Kocaeli University Faculty of Medicine. She has worked at several leading hospitals, including Oltu State Hospital, Kocaeli State Hospital, Marmara University Pendik Training and Research Hospital, and Medistate Kavacik Hospital. Dr. Kaya has made important contributions to cancer care at these institutions.

    She is known for her evidence-based approach and focus on patient outcomes. Dr. Kaya has managed many complex oncology cases. She holds accreditation from top Turkish medical faculties. Dr. Kaya is committed to improving oncology practice through ongoing professional development and clinical excellence.

  • Толығырақ оқу
Қуықты алып тастау және қалпына келтіру
$20,000 - $25,000
Іш қуысына жіті енгізілетін химиотерапия HIPEC
$28,000 - $47,000
Ақпарат

Vladimir Yutkin

  • 4.4 Жақсы 12 пікірлер
  • 29 жылдар тәжірибе
  • Израиль, Іерусалім, Hadassah Medical Center
  • Dr. Vladimir Yutkin, MD, is the Director of Urologic Oncology, Robotic, and Advanced Laparoscopic Surgery at Hadassah Medical Center. He has over 20 years of experience treating urological cancers. Dr. Yutkin also co-directs the Endo-Urology Society Fellowship. He is known for his expertise in minimally invasive surgical techniques.

    Dr. Yutkin graduated from the Hebrew University of Jerusalem in 1996. He has performed many successful procedures, helping to improve patient survival and recovery. Dr. Yutkin speaks English, Hebrew, and Russian. He is a respected leader in urologic oncology.

  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Ofer Nathan Gofrit

  • 4.4 Жақсы 12 пікірлер
  • Израиль, Іерусалім, Hadassah Medical Center
  • Urologist, Chief physician of the Urology Department
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Tamar Jablonski-Perec

  • 4.4 Жақсы 12 пікірлер
  • Израиль, Іерусалім, Hadassah Medical Center
  • Dr. Tamar Jablonski-Perec is an oncologist at Hadassah Medical Center in Jerusalem. She holds a Doctor of Medical Sciences from the Hebrew University and has experience from the renowned Sloan-Kettering Cancer Center in New York. She is the Head of Institute of Oncology, Head of Breast Cancer Treatment Center, and Professor of the Department of Oncology at the Hebrew University. She is a member of several international cancer communities and was awarded a scholarship from the Hadassah Medical School.

  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Talat Yurdakul

  • 4.4 Жақсы 30 пікірлер
  • 75 жылдар тәжірибе
  • Түркия, Істанбұл, Medical Park Göztepe Hospital Complex
  • Professor of Urology. Oncourologist

Қуықты алып тастау
$13,000 - $13,000
Ақпарат

Tolga Akman

  • 2 Жақсы 1 пікірлер
  • 23 жылдар тәжірибе
  • Түркия, Істанбұл, Medicana Bahcelievler Hospital
  • Dr. Tolga Akman is a urologist with expertise in advanced surgical procedures. He performs penis prosthesis, bladder, prostate, and kidney cancer surgeries. He is skilled in laparoscopic urology and kidney stone treatments. Dr. Akman also treats female urinary incontinence, pediatric vesicoureteral reflux, and performs microsurgical varicocele procedures. He offers penis enlargement and correction of Peyronie’s disease.

    Dr. Akman completed his residencies at Istanbul University School of Medicine and Bezmialem Vakıf University. He is now a Professor of Medicine at Medicana Hospital Bahcelievler. He is active in both clinical practice and academic work in urology.

  • Толығырақ оқу
Дәрігерге бару
Бағасы сұрау бойынша
Ақпарат

Chaitainya Borde

  • Жаңа
  • 10 жылдар тәжірибе
  • Үндістан, Нашік, HCG Manavata Cancer Centre
  • Dr. Chaitainya Borde is a nuclear medicine specialist with 12 years of clinical experience. He is skilled in advanced nuclear scans, PET-CT imaging, and nuclear cardiology. He works in both diagnostic and therapeutic nuclear medicine.

    Dr. Borde has performed over 30,000 PET scans. He has managed more than 1,000 thyroid cancer patients. He is experienced in radioiodine and Lu-177 RN therapies. He has also published research papers in respected medical journals, showing his dedication to academic work.

  • Толығырақ оқу
Иммунотерапия Кейтрудой (Пембролизумаб)
$3,200 - $4,000
Ақпарат

Ravindra Tandale

  • Жаңа
  • 16 жылдар тәжірибе
  • Үндістан, Нашік, HCG Manavata Cancer Centre
Иммунотерапия Кейтрудой (Пембролизумаб)
$3,200 - $4,000
Ақпарат

Shruti Kate

  • Жаңа
  • 14 жылдар тәжірибе
  • Үндістан, Нашік, HCG Manavata Cancer Centre
  • Dr. Shruti Kate is an experienced oncologist. She specializes in treating lung, breast, gynecological, and genitourinary cancers. She earned her MBBS from Lady Hardinge Medical College. She completed her MD in Internal Medicine at Maulana Azad Medical College. She also holds a DM in Medical Oncology from Tata Memorial Hospital, Mumbai.

    Dr. Kate has managed both conservative and surgical cancer treatments. She is skilled in complex procedures such as the Whipple surgery. She is a member of several leading oncology societies, including ASCO, ESMO, IASCLC, ISMPO, and IOS. Her research on lung cancer received the only travel award from India at the 2018 World Conference on Lung Cancer.

  • Толығырақ оқу
Иммунотерапия Кейтрудой (Пембролизумаб)
$3,200 - $4,000
Ақпарат

Shaunak Valame

  • Жаңа
  • 9 жылдар тәжірибе
  • аккредитациялар:
  • Үндістан, Нашік, HCG Manavata Cancer Centre
  • Dr. Shaunak Valame is an MD in Internal Medicine and holds a DNB in Medical Oncology. He received advanced training at Indraprastha Apollo Hospital in New Delhi. He also worked as a Registrar at Jawaharlal Nehru Cancer Hospital in Bhopal. Dr. Valame has presented his research at international forums, including the Gastrointestinal Cancer Symposium in San Francisco.

    He is known for his work in targeted cancer therapies. He has given lectures at the International Winter School of Oncology at AIIMS Bhopal. Dr. Valame is accredited by the American Society of Clinical Oncology. He is committed to advancing cancer research and clinical care.

  • Толығырақ оқу
Иммунотерапия Кейтрудой (Пембролизумаб)
$3,200 - $4,000
Ақпарат

Sridhar P.S.

  • Жаңа
  • 29 жылдар тәжірибе
  • Үндістан, Нашік, HCG Manavata Cancer Centre
  • Dr. Sridhar P.S. is a skilled radiation oncologist. He earned his Bachelor of Medicine from Mysore University. He completed his MD in Radiotherapy at Banaras Hindu University. He also holds a Diplomate of the National Board in Radiotherapy. This shows his advanced training and dedication to quality care.

    Dr. Sridhar is a member of several professional groups. These include the Association of Radiation Oncology of India, Society for Neuro-Oncology, Bangalore Oncology Group, and the Indian Association of Hyperthermia Oncology. He is known for his effective cancer treatments and focus on new therapies. His work has made a positive impact in the field of oncology.

  • Толығырақ оқу
Иммунотерапия Кейтрудой (Пембролизумаб)
$3,200 - $4,000
Ақпарат